Trials Annotator

Trial NCT02512679

Org. Study IDs: CCI-06-00177

Last trial update was posted on 2017-02-27

MeSH Interventions

Cyclophosphamide

MeSH Conditions

Anemia, Diamond-Blackfan Genetic Diseases, Inborn Granulomatous Disease, Chronic Immunologic Deficiency Syndromes Lymphoproliferative Disorders Metabolic Diseases Thalassemia Wiskott-Aldrich Syndrome

Other Conditions

Allogeneic Transplantation Bone Marrow Transplantation Chronic Granulomatous Disease Combined Immune Deficiency Diamond-Blackfan Anemia Genetic Diseases Pediatrics Peripheral Blood Stem Cell Transplantation Stem Cell Transplantation X-linked Lymphoproliferative Disease

Stopping Reasons

Optimal dose obtained for engraftment and minimizing toxicity

Limitations And Caveats

De-escalation was not ensued. All enrolled subjects engrafted without toxicity for dose level one.

Result Publications

Mahadeo KM, Weinberg KI, Abdel-Azim H, Miklos DB, Killen R, Kohn D, Crooks GM, Shah AJ, Kharbanda S, Agarwal R, Kapoor N. A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor. Biol Blood Marrow Transplant. 2015 Mar;21(3):440-4. doi: 10.1016/j.bbmt.2014.11.005. Epub 2014 Nov 13. [PMID: 25459642] [DOI: 10.1016/j.bbmt.2014.11.005]

Annotations

Category Annotations

No annotators decided on categories yet

Intervention Annotations

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition